Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma

Therapeutic Advances in Medical Oncology

Volumn 7, Issue 2, 2015, Pages 122-136

  Welsh, Sarah J ^a   Corrie, Pippa G ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

BRAF inhibitor; dabrafenib; management; MEK inhibitor; melanoma; toxicity; trametinib; vemurafenib

Indexed keywords

B RAF KINASE INHIBITOR; CORTICOSTEROID; DABRAFENIB; LOPERAMIDE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; STEROID; SUNSCREEN; TRAMETINIB; VEMURAFENIB;

ACNE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALGORITHM; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAF GENE; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL SEROUS RETINOPATHY; CHILL; DIARRHEA; DRUG SAFETY; EYE TOXICITY; FATIGUE; FEVER; GENE MUTATION; GENERAL PRACTITIONER; HEADACHE; HEART ARRHYTHMIA; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERKERATOSIS; HYPERTENSION; INTERSTITIAL LUNG DISEASE; KERATOACANTHOMA; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIVER TOXICITY; METASTATIC MELANOMA; NEUTROPENIA; ONCOGENE; PERICARDITIS; PERIPHERAL EDEMA; PHOTOSENSITIVITY; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; RASH; RETINA DETACHMENT; RETINA VEIN OCCLUSION; SIDE EFFECT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84924811524     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834014566428     Document Type: Review

References (24)

1. Andrews M. Behren A. Chionh F. Mariadason J. Vella L. Do H. et al. (2013) BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. J Clin Oncol 31: e448–e451.
2. Anker C. Ribas A. Grossmann A. Chen X. Narra K. Akerley W. et al. (2013) Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 31: e283–e287.
3. Ascierto P. Minor D. Ribas A. Lebbe C. O'Hagan A. Arya N. et al. (2013) Phase II trial (BREAK-2) of the BRAFi dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 31: 3205–3211.
4. Babacan T. Türkbeyler I. Balakan O. Pehlivan Y. Suner A. Kısacık B. (2014) A case of vemurafenib-induced polyarthritis in a patient with melanoma: how to manage it? Int J Rheum Dis 12 May [Epub ahead of print].
5. Callahan M. Rampal R. Harding J. Klimek V. Chung Y. Merghoub T. et al. (2012) Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 367: 2316–2321.
6. Chapman P. Hauschild A. Robert C. Haanen J. Ascierto P. Larkin J. et al. (2011) BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507–2516.
7. Das Thakur M. Salangsang F. Landman A. Sellers W. Pryer N. Levesque M. et al. (2013) Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494: 251–256.
8. Flaherty K. Infante J. Daud A. Gonzalez R. Kefford R. Sosman J. et al. (2012 a) Combined BRAF and MEK inhibition in melanoma with BRAF V 600 mutations. N Engl J Med 367: 1694–1703.
9. Flaherty K. Robert C. Hersey P. Nathan P. Garbe C. Milhem M. et al. (2012 b) METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367: 107–114.
10. Hauschild A. Grob J. Demidov L. Jouary T. Gutzmer R. Millward M. et al. (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358–365.
11. Hauschild A. Grob J. Demidov L. Jouary T. Gutzmer R. Millward M. et al. (2013) An update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). J Clin Oncol 31(Suppl.): abstract 9013.
12. Infante J. Fecher L. Falchook G. Nallapareddy S. Gordon M. Becerra C. et al. (2012) Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEKi trametinib: a phase 1 dose-escalation trial. Lancet Oncol 13: 773–781.
13. Koop A. Satzger I. Alter M. Kapp A. Hauschild A. Gutzmer R. (2014) Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma. Br J Dermatol 170: 220–222.
14. Larkin J. Del Vecchio M. Ascierto P. Krajsova I. Schachter J. Neyns B. et al. (2014) Vemurafenib in patients with BRAFV 600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 15: 436–444.
15. Long G. Stroyakovsky D. Gogas H. Levchenko E. de Braud F. Larkin J. et al. (2014) COMBI-d: a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. J Clin Oncol 32(Suppl.): abstract 9011.
16. Mahoney K. Ackerman A. Cho D. McDermott D. Peters T. Atkins M. (2013) Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication. J Clin Oncol 31: e364–e366.
17. Renouf D. Velazquez-Martin J. Simpson R. Siu L. Bedard P. (2012) Ocular toxicity of targeted therapies. J Clin Oncol 30: 3277–3288.
18. Ribas A. Flaherty K. (2011) BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 8: 426–433.
19. Ribas A. Hodi F. Callahan M. Konto C. Wolchok J. (2013) Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368: 1365–1366.
20. Seghers A. Wilgenhof S. Lebbé C. Neyns B. (2012) Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res 22: 466–472.
21. Sinha R. Edmonds K. Newton-Bishop J. Gore M. Larkin J. Fearfield L. (2012) Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 167: 987–994.
22. Sosman J. Kim K. Schuchter L. Gonzalez R. Pavlick A. Weber J. et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707–714.
23. Su F. Viros A. Milagre C. Trunzer K. Bollag G. Spleiss O. et al. (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366: 207–215.
24. Zimmer L. Livingstone E. Hillen U. Dömkes S. Becker A. Schadendorf D. (2012) Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 148: 357–361.